Can medical devices be advertised on social media in Europe?
Advertising medical devices on social media in Europe is complex, requiring compliance with diverse national regulations and careful planning to avoid legal pitfalls.
MoreLife sciences & healthcare
Our Life Sciences and healthcare team work with some of the largest pharmaceutical, biotechnology, and medical device companies and healthcare providers in the world to a diverse collective of small-to-medium-sized start-up enterprises ready to upscale their business, and many companies in between.
Find out moreAdvertising Medical Devices European Comparison Tool
Looking to promote your medical device products in Europe? Access our comparison tool to manage regulatory challenges across multiple jurisdictions.
Access hereThe Unified Patent Court (UPC)
The UPC and Unitary Patent will introduce the most radical changes to patent litigation in Europe in 40 years.
Read our guide to the UPCBeginner's guide to medicines advertising in Europe
Regulatory oversight in Europe strictly governs pharmaceutical advertising, including content, presentation, and audience, although with some variation between countries. Compliance with these regulations is essential to avoid sanctions and third-party damages claims.
2 of 4 Insights
National penalties for breach of medical device advertising rules
Penalties for breaching advertising laws for medical devices or IVDs in Europe include administrative fines, criminal fines, and damages for unfair competition, but with huge variation between countries. Compliance with local laws is crucial to avoid sanctions and third party damages claims.
3 of 4 Insights
Can medical devices be advertised on social media in Europe?
Advertising medical devices on social media in Europe is complex, requiring compliance with diverse national regulations and careful planning to avoid legal pitfalls.
1 of 4 Insights
Taking care around use of social media for medicines companies
Pharmaceutical companies must exercise caution when using social media for advertising in Europe. Compliance with diverse national laws, transparency in promotional activities, and careful planning are essential.
4 of 4 Insights
Orphan drug protection
1 of 9 Insights
To use or not to use?
2 of 9 Insights
Updated post-market surveillance (PMS) rules for medical devices in the UK: differences from the EU regulations
3 of 9 Insights
Reporting clinical trial results to the market
4 of 9 Insights
European Court of Justice on advertising for biocidal products: ‘Skin-friendly’ is misleading and violates EU law
5 of 9 Insights